Acceleron Pharma Inc.

Cambridge, MA, United States

Acceleron Pharma Inc.

Cambridge, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Acceleron Pharma Inc. | Date: 2017-01-23

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.


Patent
Acceleron Pharma Inc. | Date: 2016-08-24

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of BMP9 and/or BMP10, ligands for ALK1, may also be used to inhibit angiogenesis in vivo.


In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.


Compositions for increasing red blood cell levels or treatment of anemia comprising erythropoietin receptor activators and a variant Activin RIIB (ActRIIB) polypeptide having a leucine residue replaced by a acidic amino acid residue, where the variant ActRIIB polypeptide has a reduced affinity for activin B and may be called a GDF trap. Methods for the use of these compositions.


The present invention relates to follistatin-Fc fusion proteins that have effects in the tissue of administration (such as an injected muscle), rather than systemic effects. The Fc domain results in dimerization of the follistatin-Fc fusion protein, and provides enhanced tissue retention. The description includes fusion proteins comprising a human follistatin polypeptide consisting of FST288, FST291 (a non-natural truncated follistatin) or FST315; and a human IgGl or IgG2 Fc domain.


In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sickle-cell disease or one or more complications associated with sickle-cell disease.


Patent
Acceleron Pharma Inc. | Date: 2017-04-19

The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.


In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof comprising administering an effective amount of an agent/s that inhibits activin B and/or GDF11. Subjects in need include, for example, subject having an anemia and subjects have an ineffective erythropoiesis disorder.


Patent
Acceleron Pharma Inc. | Date: 2017-06-21

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.


Some aspects of this disclosure provide methods and compositions for the treatment of cancer, for example, head and neck cancer, in a subject using ALK1 inhibitors, e.g., ALK1-ECD polypeptides, ALK1-Fc fusion proteins, or ALK1-inhibitory antibodies. In some embodiments, methods and compositions are provided for treating certain cancers with ALK1 inhibitors in combination with a chemotherapeutic platinum agent. In some embodiments, methods are provided for identifying whether a cancer in a subject will react to treatment with an ALK1 antagonist, either alone or in combination with a chemotherapeutic platinum agent, for example, based on a determination that the cancer or the subject is positive for human papilloma virus.

Loading Acceleron Pharma Inc. collaborators
Loading Acceleron Pharma Inc. collaborators